Vanzacaftor

Overview

Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator ( CFTR ). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor ( HY-15448 ) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > CFTR | Products > Signaling Pathways > Chloride Channel

Product Information

• Catalog No.: HY-145603
• CAS No.: 2374124-49-7
• Molecular Formula: C32H39N7O4S
• Molecular Weight: 617.76
• Purity: 98.72%
• Storage: -20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (4.05 mM); Clear solution
• Availability: In-stock

Source

Original product source